Valvular Heart Disease: Difference between revisions

no edit summary
No edit summary
No edit summary
Line 79: Line 79:
Aortic stenosis is assessed by estimating the mean systolic pressure gradient and aortic valve area (AVA). The normal aortic valve area is 3-4 cm2.  Mild aortic stenosis is defined as an aortic valve area 1.5 cm2, mean gradient less than 25 mm Hg, or jet velocity less than 3.0 m per second, moderate aortic stenosis as an area of 1.0 to 1.5 cm2, mean gradient 25 to 40 mmHg, or jet velocity 3.0 to 4.0 m per second. A valve area of <1 cm2,  a mean gradient greater than 40 mm Hg, or jet velocity greater than 4.0 m per second  implies severe aortic stenosis The valve area may decrease by as much as 0.12 ±  0.19cm2  per year.<cite>OttoBurwaskLegget</cite> In late stages of severe aortic stenosis, cardiac output declines due to systolic dysfunction of the left ventricle, with a decline in the transvalvular gradient.
Aortic stenosis is assessed by estimating the mean systolic pressure gradient and aortic valve area (AVA). The normal aortic valve area is 3-4 cm2.  Mild aortic stenosis is defined as an aortic valve area 1.5 cm2, mean gradient less than 25 mm Hg, or jet velocity less than 3.0 m per second, moderate aortic stenosis as an area of 1.0 to 1.5 cm2, mean gradient 25 to 40 mmHg, or jet velocity 3.0 to 4.0 m per second. A valve area of <1 cm2,  a mean gradient greater than 40 mm Hg, or jet velocity greater than 4.0 m per second  implies severe aortic stenosis The valve area may decrease by as much as 0.12 ±  0.19cm2  per year.<cite>OttoBurwaskLegget</cite> In late stages of severe aortic stenosis, cardiac output declines due to systolic dysfunction of the left ventricle, with a decline in the transvalvular gradient.


<div align="center">
{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="80%"
{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="80%"
|-
|-
Line 101: Line 102:
|greater than 4.0 m per second
|greater than 4.0 m per second
|}
|}
</div>


== Clinical Presentation ==
== Clinical Presentation ==
Line 171: Line 173:
No medical treatment has proven to delay the progression of aortic stenosis. Surgery is inevitable for symptomatic patients. Patients at prohibitive risk for intervention may benefit from medical treatment including digitalis, diuretics, ACE inhibitors, or angiotensin receptor blockers, if experiencing heart failure. Beta-blockers should be avoided in these circumstances.  
No medical treatment has proven to delay the progression of aortic stenosis. Surgery is inevitable for symptomatic patients. Patients at prohibitive risk for intervention may benefit from medical treatment including digitalis, diuretics, ACE inhibitors, or angiotensin receptor blockers, if experiencing heart failure. Beta-blockers should be avoided in these circumstances.  


<div align="center">
{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="80%"
{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="80%"
|-
|-
Line 195: Line 198:
#AVR is not useful for the prevention of sudden death in asymptomatic patients with AS who have none of the findings listed under the Class IIa/IIb recommendations. (Level of Evidence: B)
#AVR is not useful for the prevention of sudden death in asymptomatic patients with AS who have none of the findings listed under the Class IIa/IIb recommendations. (Level of Evidence: B)
|}
|}
</div>
{| border="0" cellpadding="1" cellspacing="1" width="100%"
{| border="0" cellpadding="1" cellspacing="1" width="100%"
|-
|-
Line 218: Line 223:
In 2002, the first transcatheter aortic valve implantation was performed by Dr. Alain Cribier <cite>Cribier</cite>. A transcatheter aortic valve implantation is a less invasive treatment option for patients at prohibitive risk for conventional aortic valve replacement.  In this technique, the native valve is not excised. After balloon valvuloplasty, the prosthetic valve is implanted in the aortic position, with the frame of the prosthesis covering the native valve. The bioprosthesis can be implanted retrograde or antegrade. Currently 4 different approaches may be used in this technique. (table…). Transcatheter aortic valve implantation is assessed in randomized clinical trials and registries.  
In 2002, the first transcatheter aortic valve implantation was performed by Dr. Alain Cribier <cite>Cribier</cite>. A transcatheter aortic valve implantation is a less invasive treatment option for patients at prohibitive risk for conventional aortic valve replacement.  In this technique, the native valve is not excised. After balloon valvuloplasty, the prosthetic valve is implanted in the aortic position, with the frame of the prosthesis covering the native valve. The bioprosthesis can be implanted retrograde or antegrade. Currently 4 different approaches may be used in this technique. (table…). Transcatheter aortic valve implantation is assessed in randomized clinical trials and registries.  


{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="100%"
<div align="center">
{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="80%"
|-
|-
! The current 4 different approaches are:
! The current 4 different approaches are:
Line 230: Line 236:
|Transsubclavian, retrograde
|Transsubclavian, retrograde
|}
|}
</div>


== Prognosis ==
== Prognosis ==
Line 324: Line 331:
In contrast to the compensatory mechanism in mitral valve regurgitation, a modest concentric left ventricular hypertrophy accompanies the eccentric hypertrophy, with a normal mass-to-volume ratio.<cite>FeiringRumberger</cite> In a chronic state, progressive left ventricle dilatation leads to pre- and afterload mismatch. With gradually decompensation and deterioration of systolic function, the ventricle is not able to sustain perfusion.  
In contrast to the compensatory mechanism in mitral valve regurgitation, a modest concentric left ventricular hypertrophy accompanies the eccentric hypertrophy, with a normal mass-to-volume ratio.<cite>FeiringRumberger</cite> In a chronic state, progressive left ventricle dilatation leads to pre- and afterload mismatch. With gradually decompensation and deterioration of systolic function, the ventricle is not able to sustain perfusion.  


{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="100%"
<div align="center">
 
{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="80%"
|-
|-
!Causes of chronic aortic regurgitation 
!Causes of chronic aortic regurgitation 
Line 330: Line 339:
|
|
#Aortic root/annular dilation
#Aortic root/annular dilation
|-
|
#Congenital bicuspid valve
#Congenital bicuspid valve
|-
|
#Previous infective endocarditis
#Previous infective endocarditis
|-
|
#Rheumatic
#Rheumatic
|-
|
#In association with other diseases
#In association with other diseases
|}
|}
</div>
{| border="0" cellpadding="1" cellspacing="1" width="100%"
{| border="0" cellpadding="1" cellspacing="1" width="100%"
|-
|-
Line 370: Line 389:
The relative reduction of myocardial blood supply due to increased demand and/or associated obstructive coronary artery disease may cause angina. Angina may be treated by reducing aortic regurgitation, reduction of myocardial demand of revascularization of the myocardium. Clinical heart failure is treated with traditional therapy, including digitalis, diuretics, and ACEI. In severe heart failure, parenteral inotropic and vasodilator therapy may be needed.   
The relative reduction of myocardial blood supply due to increased demand and/or associated obstructive coronary artery disease may cause angina. Angina may be treated by reducing aortic regurgitation, reduction of myocardial demand of revascularization of the myocardium. Clinical heart failure is treated with traditional therapy, including digitalis, diuretics, and ACEI. In severe heart failure, parenteral inotropic and vasodilator therapy may be needed.   


<div align="center">
{| class="wikitable" border="1" cellpadding="0" cellspacing="0"
{| class="wikitable" border="1" cellpadding="0" cellspacing="0"
|-
|-
Line 388: Line 408:
#Vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal LV function or mild to moderate LV systolic dysfunction who are otherwise candidates for AVR. (Level of Evidence: C)
#Vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal LV function or mild to moderate LV systolic dysfunction who are otherwise candidates for AVR. (Level of Evidence: C)
|}
|}
</div>


====Surgical treatment====
====Surgical treatment====
Line 396: Line 417:
Although the prosthetic valve replacement remains the standard for aortic valve regurgitation, aortic valve repair procedures are performed with a combination of different surgical techniques.  The quality of the cusps is essential for repair. The annulus and sinotubular junction can be surgically readapted to the cusps, eliminating the regurgitation.
Although the prosthetic valve replacement remains the standard for aortic valve regurgitation, aortic valve repair procedures are performed with a combination of different surgical techniques.  The quality of the cusps is essential for repair. The annulus and sinotubular junction can be surgically readapted to the cusps, eliminating the regurgitation.


{| class="wikitable" border="1" cellpadding="0" cellspacing="0"
<div align="center">
{| class="wikitable" border="1" cellpadding="0" cellspacing="0" width="80%"
|-
|-
!Current Guidelines 
!Current Guidelines 
Line 410: Line 432:
# An asymptomatic adolescent with chronic severe AR* with onset of ST depression or T-wave inversion over the left precordium on ECG at rest may be considered for aortic valve repair or replacement. (Level of Evidence: C)
# An asymptomatic adolescent with chronic severe AR* with onset of ST depression or T-wave inversion over the left precordium on ECG at rest may be considered for aortic valve repair or replacement. (Level of Evidence: C)
|}
|}
</div>


== Mitral Stenosis ==
== Mitral Stenosis ==
467

edits